New Clinical Trial Matching Service Helps CLL Patients Stay Connected with Research Options

Share Article

EmergingMed announced the launch of a new clinical trial matching service that helps people with chronic lymphocytic leukemia connect with research studies of new cancer therapies in development.

EmergingMed announced the launch of a new clinical trial matching service that helps people with chronic lymphocytic leukemia connect with research studies of new cancer therapies in development. Using EmergingMed’s proprietary clinical trial matching system, this phone- and web-based service offers a customized and confidential tool that allows patients to stay informed about available clinical studies and locations in the U.S. and Canada. The service is now available online at http://www.cllclinicalstudies.com/ and by phone at 1-855-216-0103.

Chronic lymphocytic leukemia (CLL) is a slowly progressing cancer of the blood and bone marrow that leads to an excess of abnormal lymphocytes, the white blood cells that help to fight infection. CLL is the most common type of leukemia in the U.S., and the American Cancer Society estimates that over 15,600 Americans will be diagnosed with CLL in 2013. Treatment for CLL varies depending on a person’s symptoms and medical history.

One treatment option to consider at each stage is participation in a clinical trial, a research study designed to evaluate the safety and effectiveness of new therapies in development or new ways to use existing therapies. Clinical trials enroll patients at very specific moments in the course of their disease and require participants to meet strict eligibility criteria based on their symptoms, stage and treatment history. EmergingMed’s new CLL Clinical Trial Matching Service is a confidential, personalized service that helps people with CLL in a matter of minutes to identify clinical trials for which they may qualify. Since a patient’s symptoms change over time, the CLL Clinical Trial Matching Service also provides alerts on new CLL clinical trial options as they become available.

"With the overwhelming number of information sources for cancer clinical trials, it is extremely challenging for CLL patients or caregivers to identify clinical trials that may be an appropriate fit,” said Courtney Hudson, CEO and co-founder of EmergingMed. “The CLL Clinical Trial Matching Service makes it easy for patients to search for, and connect with, trials that match their unique needs.”    

Clinical Trial Navigators at the CLL Clinical Trial Matching Service help patients find clinical trials that match their specific diagnosis, disease stage, and treatment history. By coordinating this connection among patients, clinical trials, and cancer researchers, the CLL Clinical Trial Matching Service ensures that patients have accurate, actionable information at the right time throughout the course of this chronic disease.

“At EmergingMed, we are committed to empowering CLL patients to consider clinical trials as one of their treatment options each time they and their health care team are making a decision about their treatment,” said Hudson. “By engaging individual patients, we believe we are helping to optimize enrollment in clinical trials and accelerate the discovery of new and better CLL therapies.”

For more information about EmergingMed, call 1-877-601-8601 ext. 385 or email CLL-CTA(at)emergingmed(dot)com.

SOURCE EmergingMed
Website:     http://www.emergingmed.com
    http://www.cllclinicalstudies.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Courtney Hudson
Visit website